US Neurology Editorial Board member, Daniel Hanley (Johns Hopkins Medicine, Baltimore, Maryland, USA), provides his positive insights on MISTIE III, a clinical trial investigating the efficacy and safety of minimally invasive surgery with thrombolysis in intracerebral hemorrhage evacuation, which failed to meet its primary endpoint of improved functional outcome at 1 year.
Questions
1. Could you tell us a little about the MISTIE procedure for the surgical removal of spontaneous intracerebral hemorrhage? (0:04)
2. What were the findings of the MISTIE III study? (1:14)
3. What lessons have been learned from MISTIE III and what will be the next steps in this research (3:12)
4. What are your hopes for the future of this research? (4:52)
Speaker disclosures: Daniel Hanley has nothing to disclose in relation to this video interview.
Filmed at the American Academy of Neurology (AAN) Annual Meeting, Philadelphia, USA, May 2019.
